Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00108
|
|||||
| Drug Name |
Testosterone
|
|||||
| Synonyms |
(17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one; AA 2500; Andro 100; AndroGel; Androderm; Androderm (TN); Androgel (TN); Androlin; Andronaq; Andronate 100; Andronate 200; Andropatch; Andropository 200; Androsorb; Androst-4-en-17beta-ol-3-one; Andrusol; Andryl 200; Beta testosterone; CDB 111C; CMC_13449; COL 1621; CP 601B; Cristerona T; Cristerone T; Delta(sup 4)-Androsten-17(beta)-ol-3-one; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Depotest; Everone 200; Geno-cristaux gremy; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Malestrone (amps); Malogen in Oil; Malogen, aquaspension injection; Mertestate; Neo-Hombreol F; Neo-testis; Neotestis; Oreton; Oreton F; Oreton-F; Orquisteron; Perandren; Percutacrine androgenique; Primotest; Primoteston; Relibra; Scheinpharm Testone-Cyp; Striant; Striant (TN); Sustanon; Sustanone; Sustason 250; Synandrol F; T-Cypionate; Teslen; Testamone 100; Testandrone; Testaqua; Testiculosterone; Testim; Testim (TN); Testobase; Testoderm; Testoderm Tts; Testogel; Testoject-50; Testolin; Testopel Pellets; Testopropon; Testosteroid; Testosteron; Testosterona; Testosterona [INN-Spanish]; Testosterone (JAN/USP); Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testosteronum; Testosteronum [INN-Latin]; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testred Cypionate 200; Testrin-P.A; Testro AQ; Testrone; Testryl; Trans-Testosterone; Virilon IM; Virormone; Virosterone
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Osteoporosis [ICD11: FB83.1] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H28O2
|
|||||
| Canonical SMILES |
CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
|
|||||
| InChI |
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
|
|||||
| InChIKey |
MUMGGOZAMZWBJJ-DYKIIFRCSA-N
|
|||||
| CAS Number |
CAS 58-22-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 288.4 | Topological Polar Surface Area | 37.3 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
3.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10318947
, 12012605
, 14849069
, 14873306
, 17389513
, 22400338
, 24702263
, 24870573
, 24899970
, 24900279
, 26717586
, 26717589
, 26717592
, 26717594
, 29225027
, 3136424
, 3817
, 46501387
, 46505691
, 48421877
, 48425662
, 49703436
, 50049744
, 50085980
, 53789940
, 56311126
, 56311276
, 56312112
, 56312748
, 56313357
, 56313477
, 56313560
, 56313804
, 56314183
, 56314208
, 56462804
, 57288851
, 57323115
, 584560
, 625875
, 7847143
, 7890744
, 8144176
, 8153742
, 819215
, 822362
, 822363
, 822524
, 823294
, 841439
|
|||||
| ChEBI ID |
ChEBI:17347
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Testosterone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9. | |||||
| 3 | Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008 Jun 1;14(11):3312-8. | |||||
| 4 | A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.